Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/18/21
Oncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/12/21
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/11/21
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of DirectorsGlobeNewsWire • 01/28/21
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy ProgramGlobeNewsWire • 01/14/21
Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell TherapiesGlobeNewsWire • 01/07/21
Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional SharesGlobeNewsWire • 12/14/20
Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 MillionGlobeNewsWire • 12/10/20
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 MillionGlobeNewsWire • 11/18/20
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual MeetingGlobeNewsWire • 11/11/20
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/04/20
Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing SarcomaBusiness Wire • 10/06/20
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020Business Wire • 09/21/20
Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 MillionBusiness Wire • 08/28/20
Oncternal Therapeutics' (ONCT) CEO Jim Breitmeyer on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/08/20
Oncternal Provides Business Update and Announces Second Quarter 2020 Financial ResultsBusiness Wire • 08/06/20
Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business UpdateBusiness Wire • 07/30/20